1. Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus

3. Introduction

4. ADA Practice Guidelines

5. ADA Practice Guidelines (cont)

6. EDITION I to III Meta-Analysis: Summary

7. EDITION I to III Meta-Analysis: Severe or Confirmed Hypoglycemia ≤ 3
EDITION I to III Meta-Analysis: Severe or Confirmed Hypoglycemia ≤ 3.9 mmol/L (70 mg/dL)

8. SWITCH 2: Trial Population

9. SWITCH: Hypoglycemia Risk Inclusion Criteria

10. SWITCH 2: HbA1c Over Time - Noninferiority Was Confirmed

11. SWITCH 2: Overall Symptomatic Hypoglycemia - IDeg Significantly Reduced Overall Symptomatic Hypoglycemia vs IGlar U100

12. SWITCH 2: Nocturnal Symptomatic Hypoglycemia - IDeg Significantly Reduced Nocturnal Symptomatic Hypoglycemia vs IGlar U100

13. SWITCH 2: Severe Hypoglycemia - IDeg Significantly Reduced Severe Hypoglycemia vs IGlar U100 in the Full Treatment Period

14. SWITCH 2 in Perspective: Hypoglycemia - Switch vs Phase 3a Meta-Analysis

15. DEVOTE: Trial Design

16. Baseline Medications

17. Time to First MACE

18. Incidence of Hypoglycemia

19. DEVOTE Confirmed the Results From BEGIN and SWITCH in Regard to Hypoglycemia in T2DM

20. Systematic Review: Association of Hypoglycemia With Outcomes

21. ADA Practice Guidelines (cont)

22. Adding a GLP-1 RA to Basal Insulin

23. Addition of GLP-1 RA to Basal Insulin: Change in HbA1c

24. Addition of GLP-1 RA to Basal Insulin: Change in Weight

25. Addition of GLP-1 RA or Bolus Insulin to Basal Insulin Hypoglycemia

26. Fixed-Ratio Combinations: Advantages

27. EXTRA: Real World Experience with IDegLira

28. Data of DUAL VII

29. EXTRA: Real World Experience with IDegLira (cont)

30. ADA Practice Guidelines (cont)

31. Addition of GLP-1 RA or Bolus Insulin to Basal Insulin Hypoglycemia (cont)

32. Conclusion